BioPharma Resources

Company

Ipsen

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

6

6 still marketed

Novel approvals

5

Approvals since 2021

8

Originals and new uses

Phase 3 trials

84

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Bylvay new use OrphanDec 19, 2025
  • Sohonos new use OrphanMar 13, 2025
  • Iqirvo approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanJun 10, 2024
  • Increlex new use OrphanMar 15, 2024
  • Onivyde new use OrphanFeb 13, 2024
  • Sohonos approved NovelPriority reviewOrphanAug 16, 2023
  • Bylvay new use Priority reviewOrphanJun 13, 2023
  • Bylvay approved NovelPriority reviewOrphanJul 20, 2021
  • Somatuline Depot new use OrphanSep 15, 2017
  • Onivyde approved Priority reviewOrphanOct 22, 2015

Drugs in development (7)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • CorabotaseIPN10200Phase 37 trials

    Ipsen · Moderate to Severe Glabellar Lines, Spasticity, Moderate to Severe Upper Facial Lines

  • IPN60340Phase 31 trial

    Ipsen · Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia

  • IPN01194Phase 21 trial

    Ipsen · Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma

  • IPN01195Phase 21 trial

    Ipsen · Advanced Solid Tumor

  • IPN01203Phase 21 trial

    Ipsen · Advanced Solid Tumor, Metastatic Solid Tumor

  • IPN60300Phase 21 trial

    Ipsen · Locally Advanced Solid Tumor, Metastatic Solid Tumor

  • IPN60350Phase 21 trial

    Ipsen · Neoplasms, Neoplasm Metastasis, Neoplastic Processes

Recruiting Phase 3 trials

Largest first.

Marketed drugs (6)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.